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Abstract
Background: We performed a prospective, randomized, placebo-controlled study aimed to evaluate the efficacy
and safety of a sedation protocol based on intranasal Ketamine and Midazolam (INKM) administered by a mucosal
atomizer device in uncooperative children undergoing gastric aspirates for suspected tuberculosis. Primary outcome:
evaluation of Modified Objective Pain Score (MOPS) reduction in children undergoing INKM compared to the placebo
group. Secondary outcomes: evaluation of safety of INKM protocol, start time sedation effect, duration of sedation and
evaluation of parents and doctors’ satisfaction about the procedure.
Methods: In the sedation group, 19 children, mean age 41.5 months, received intranasal Midazolam (0.5 mg/kg) and
Ketamine (2 mg/kg). In the placebo group, 17 children received normal saline solution twice in each nostril. The child’s
degree of sedation was scored using the MOPS. A questionnaire was designed to evaluate the parents’ and doctors’
opinions on the procedures of both groups.
Results: Fifty-seven gastric washings were performed in the sedation-group, while in the placebo-group we performed
51 gastric aspirates. The degree of sedation achieved by INMK enabled all procedures to be completed without
additional drugs. The mean duration of sedation was 71.5 min. Mean MOPS was 3.5 (range 1-8) in the sedation-group,
7.2 (range 4-9) in the placebo-group (p <0.0001). The questionnaire revealed high levels of satisfaction by both doctors
and parents in the sedation-group compared to the placebo-group. The only side effect registered was post-sedation
agitation in 6 procedures in the sedation group (10.5%).
Conclusions: Our experience suggests that atomized INKM makes gastric aspirates more acceptable and easy to
perform in children.
Trial registration: Unique trial Number: UMIN000010623; Receipt Number: R000012422.
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Background
Tuberculosis (TB) is among the top 10 causes of childhood
death worldwide. Because children with pulmonary TB are
unable to produce sputum, gastric aspirate is the procedure
of choice for microbiologic confirmation of disease.
Attention to the technique of gastric aspirate collection
has been demonstrated to improve the yield of this
diagnostic tool [1], but this procedure requires children to
be cooperative and a noninvasive route for sedative drug
administration, such as intranasal, may be useful in
obtaining a short-time sedation. This is particularly
important if we consider that nasogastric tube insertion
(NGTI) is one of the most painful and uncomfortable
procedures performed in children [2-5]. Several methods
have been proposed to reduce the discomfort of NGTI,
such as using lubricant gel, topical Lidocaine sprays,
Lidocaine gel as well as other non-medical strategies [6],
but none showed a strong benefit, particularly in children.
In fact, despite all these methods, NGTI following the
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administration of water-soluble lubricating gel is still one
of the most used methods in many medical centers
[7,8]. Intranasal Midazolam (INM) has been found to be
effective in doses ranging from 0.2 to 0.5 mg/kg when
used for conscious sedation [9]. The intranasal route is
preferable since it obviates the need for intravenous
access, is easily accessible and allow a more rapid rate of
absorption compared to the oral route [10,11]. Although
most studies investigating INM administered the drug by
drop instillation, new methods such as spray devices are
being explored. Atomization devices were assessed in
several studies and showed good tolerance, safety and
efficacy [12]. A Mucosal Atomizer Device (MAD) delivers
medications via a fine spray over a broad surface area in the
nasal cavity. It also reduces sneezing and coughing com-
pared to other devices [9]. Ketamine has local anesthetic
properties and interacts with the N-methyl-D-aspartate
receptors both in the vascular endothelium and in the
central nervous system, thus attenuating the afferent
and central pain pathways [13,14]. Its activity has
some advantages, such as preservation of respiratory
reflexes and an intrinsic positive inotropic effect [15].
It is an excellent analgesic, sedative and amnestic
agent. Midazolam-Ketamine combination has been used
for different pediatric procedures inside and outside the
operating room, for its anxiolytic and analgesic effects, in
order to obtain more analgesia, less hypotension, the use
of a lower doses of drugs, and, consequently, a lower risk
of respiratory depression [16].
In this study we prospectively evaluated the efficacy
and safety of a sedation protocol based on intranasal
combination of Ketamine and Midazolam (INKM)
administered by MAD, in children undergoing gastric
aspirates for suspected pulmonary TB. The primary
outcome was to evaluate MOPS reduction in children
undergoing INKM compared to the placebo group.
Secondary outcomes were: evaluation of safety of INKM
protocol, start time sedation effect, duration of sedation
and evaluation of parents and doctors’ satisfaction about
the procedure.
Methods
We performed a prospective, placebo-controlled,
randomized, pilot study aimed to evaluate the efficacy
and safety of INKM in uncooperative children undergoing
gastric aspirates for suspected TB, in children admitted to
the pediatric infectious diseases unit of our Institution
(Unique trial Number: UMIN000010623; Receipt Number:
R000012422) [17].
Pre-sedation behavior was assessed on a 4-point
scale (1 = calm, cooperative; 2 = anxious but reassurable;
3 = anxious and not reassurable; 4 = crying or resisting) by
an anesthesiologist who was blinded to the group of the
child. Children were included if they were <14 years old
and had a pre-sedation behavior ≥ 3. Children were
excluded if they had an ASA classification of III or higher,
a known allergy to benzodiazepines, an upper respiratory
tract infection with nasal discharge, a known liver disease
or respiratory distress, known allergy to ketamine, and
age > 14 years (168 months). An independent investigator,
blind in both sedation and placebo group and not involved
in the observation or providing anesthesia to the child,
prepared the syringes for the two groups. In the
sedation-group, children received 2 mg/kg of Ketamine
hydrochloride administered by a physician in both nostrils
followed by 0.5 mg/kg (maximum dose 10 mg = 2 mL) of
Midazolam using a 2.5 mL syringe connected to a MAD
(Wolfe Tory Medical, Salt Lake City, Utah, USA)
(Figure 1). In the placebo-group, children received
normal saline solution (the same volume the child
would have received if in the sedation-group) in each
nostril (twice, in order to pretend the two different
drugs of the sedation-group) (Figure 2). Drugs were
administered by a blinded doctor not involved in syringe
preparation. Patients were randomly assigned to one of two
groups according to a computer-generated randomization
number enclosed in sequentially numbered envelopes
which were opened just before the procedure and
according with CONSORT statement [17]. Gastric
washings were performed on three consecutive days
early in the morning and after an overnight fasting. An
unbiased doctor (not involved in pre-sedation behaviour
assessment, nor in syringes preparation) inserted a
nasogastric tube into the child’s stomach after intranasal
drug/placebo administration (without any additional drugs
nor topical anaesthetics on nasogastic tube) and then
aspirated its contents; in case of unsuccessful or poor
aspiration, the volume of gastric aspirates was augmented
as needed by injecting in the stomach 5 mL of saline
solution (sterile water) and aspirating back [18]. The
procedure began in every case within 60 minutes
from intranasal administration (either drug or placebo);
this fix time-frame was pre-established because from our
personal experience (data not shown) sedation effect
always began within 60 minutes from drug administration.
Bloodpressure was measured at baseline and at 5 min
intervals. Pulse oximetry was continuously monitored and
the lowest oxygen saturation (O2 sat) was recorded. ‘Start
time’ (sedation effect onset), ‘end time’ (end of the
sedation effect) and duration of sedation (difference
between the end and start times) were registered. The
child’s degree of sedation and reactivity during the
procedures were scored by an unbiased doctor, not
involved in pre-sedation behaviour assessment, nor in
syringes preparation, and nor in NGTI. This doctor used
the Modified Objective Pain Score (MOPS), modified for
children under 2 years of age, according to author’s indica-
tions, which is also appropriate for children aged 2-11 years.
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Figure 1 The Mucosal Atomiser Device (MAD) used to deliver medications via a fine spray in the nasal cavity.
Enrollment




Analysed  (n = 17)
Excluded from analysis (n = 0) 
Allocated to Placebo (n = 17) 
Lost to follow-up (n = 0) 
Discontinued intervention (n = 0) 
Allocated to intervention (n = 19)
Received allocated intervention (n = 19)
Lost to follow-up  (n = 0)
Discontinued intervention (n = 0)
Analysed  (n=19 )
Excluded from analysis (n = 0) 
Excluded  (n = 12) 
Not meeting inclusion criteria (n = 6) 
Declined to participate (n = 5) 
Other reasons (n = 0) 
Assessed for eligibility (n = 47)
Figure 2 Patients allocation (CONSORT).
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MOPS has already been tested for both post-operative and
non post-operative pain in children [19,20].
The score ranges from 0 to 10 (the higher the score, the
greater the pain experienced for the child). Drug efficacy,
safety, tolerability and procedure times were recorded by
an unbiased blinded doctor who did not participate in the
sedation and procedures. Risks, possible discomforts and
benefits were explained to the parents and they were
required to sign an informed consent form prior to the
procedure. At the end of sedation, the unbiased blinded
doctor submitted a questionnaire to the medical staff who
did not participate in the sedation but performed the
painful procedure, and to the patient’s parents. Physicians
and parents of both groups indicated on a visual analogue
scale (‘0’ for worst, ‘10’ for best) the usefulness of the drug,
changes in the child’s and parents’ outlooks and whether
they would recommend the sedation by MAD to other
physicians and parents. The same unbiased blinded doctor
evaluated all procedures in order to minimize inter
observed variability. Informed consent was obtained from
every child’ parent. Ethics approval was obtained from the
Ethics Committee of our Hospital.
Statistical analysis
Univariate linear regression testing was used to measure
the correlation of MOPS, start time, end time and length of
sedation with the number of procedures, children’s weight
and age. MOPS in the sedation-group was compared with
MOPS in the placebo-group by using unpaired t-test. A
P value <0.05 was considered significant. Statistical analysis
was performed using SPSS v 17. MOPS was the primary
outcome of this study, which allowed the sample size to be
calculated on that basis. A retrospective review of our
database concerning gastric aspirates for TB in the previous
2 years yielded a MOPS (mean ± SD) of 7 ± 2. Calculations
derived a sample size of 17 children in each group to yield
80% power (with alfa .05) in detecting a reduction of 2
point in MOPS. Secondary outcomes were: evaluation of
safety of INKM protocol, start time sedation effect,
duration of sedation and evaluation of parents and
doctors’ satisfaction about the procedure.
Results
From January 1, 2009 to July 31, 2012 a total of 27
patients were recruited to the study. The sedation-group
consisted of 19 (8 males, 11 females) children (mean age
41.5 months, IC95% 24.2 to 58.9; median age 31 months,
IC 95% 18.8 to 49.3, SD 36.0, min 13, max 168) (Table 1);
fifty-seven gastric washings were performed in these
children (one child underwent the procedure twice).
Fifteen children were diagnosed with pulmonary TB, one
with latent TB infection and three with non-TB pneumonia.
The placebo-group consisted of 17 (7 males, 10 females)
children (mean age 40.6 months, IC 95% 21.3 to 59.9;
median age 33 months, IC 95% 19.2 to 48.7, SD 34.8,
min 14, max 152), all with a final diagnosis of active TB;
fifty-one gastric aspirates were performed in this group.
The two groups did not differ significantly with respect to
age, weight and ethnicity.
Sedation-group
The mean time between administering INKM and the
beginning of the effect was 22.9 min. The mean time
between administering INKM and the end of the
Table 1 Age, start times, end times and duration of the sedation effect in children undergoing procedural sedation by
intranasal Midazolam and Ketamine and MOPS achieved in both the sedation and placebo groups
Parameter Mean IC 95% Median IC 95% Standard deviation Min Max
Age (mths) sedation 41.5 24.2 to 58.9 31.0 18.8 to 49.3 36.0 13 168
Age (mnths) placebo 40.6 21.3 to 59.9 33.0 19.2 to 48.7 34.8 14 152
Start time sedation 22.9 19.2 to 26.6 24 15.4 to 26.6 13.7 6 60
Effect (min) sedation
Start time sedation Na# na na na na na
Effect (min) placebo
End time sedation effect (min) sedation 77.9 70.1 to 85.7 80 75.0 to 84.0 29.2 30 180
End time sedation effect (min) placebo Na na na na na na Na
Duration of sedation effect (min) sedation 71.5 63.8 to 79.3 72.0 65.6 to 76.6 28.9 25 176
Duration of sedation effect (min) placebo Na na na na na na Na
MOPS sedation* (IQR) 3.5 3.1 to 3.9 4.0 3.0 to 4.0 1.6 1 8
(2.5-4)
MOPS placebo* (IQR) 7.2 6.9 to 7.6 7 7.0 to 8.0 1.4 4 9
(6-8)
*p <0.0001.
#na: not applicable due to no effects of placebo.
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sedation effect was 77.9 min. The mean duration of
the sedation after INKM effect was 71.5 min. Mean
time needed to complete the procedure was 7 minutes
(range, 4-10 minutes). Mean MOPS was 3.5, interquartile
range 2.5 - 4 (Table 1). The degree of sedation achieved
enabled to perform all physician inserting NG tube and
aspirating gastric content, without the need of a second
doctor/nurse for physical restrain. In two cases (3.7% of all
57 procedures), the level of sedation obtained was low
(7 and 8, respectively) and a nurse was needed for
physical restrain. The only side effect registered was
transitory postsedation agitation in 6 out of 57 procedures
(10.5%). O2 sat levels ranged between 96% and 100%
during all time of procedure.
Placebo-group
After a mean time of 60.3 minutes from the administration
of normal saline solution in each nostril, no change in
children behavior was noted in all cases and the blinded
doctor began the procedure. Mean MOPS score was 7.2
(SD 1.4, range 4-9, interquartile range 6-8) (Table 1). Mean
time needed to complete the procedure was 7.5 minutes
(range, 5-9.8). None of the fifty-one procedures
could be performed by only one doctor, 15 (29.5%)
procedures had to be performed by two operators
(one doctor needed to perform the gastric aspirate,
one nurse for physical restrain), 36 (70.5%) proce-
dures had to be performed by three operators (one
doctor to perform the gastric aspirate, two nurses
for physical restrain); during these 36 procedures,
children needed to be wrapped up in bed sheets to
ensure the child to be blocked and the correct execution
of the procedure.
Patients’ parents and doctors’ appreciation
Patients’ parents of both groups blindly reported their
appreciation of the ease and utility of intranasal drug
administration to perform gastric aspirates. Both parents
and medical staff reported a major level of satisfaction
regarding the children’s behavior during the procedures
in the sedation-group respect to the placebo group
(Table 2).
Table 2 Parents’ and medical doctors’ responses to the questionnaire on the administration of intranasal Ketamine
and Midazolam (table A) and placebo (table B) via a mucosal atomiser device
A
Question Parents (n) Score (median) Range Doctors* (n) Score (median) Range
The use of INMK by MAD:
Helped 19 10 10-10 5/3 10 10-10
Level of child’s outlook 19 8.9 7-10 5/3 8 7-9
Level of parents’ outlook 19 9.1 8-10 5/3 9.5 9-10
Level of doctors’ outlook - - 5/3 8.5 8-10
Level of child’s tolerance of procedures 19 8.7 7-10 5/3 8.2 7-9
Would recommend to other parents 19 9.3 9-10 - -
Would recommend to other doctors - - 5/3 9.4 9-10
Would like to see MAD used routinely 19 9.8 9-10 5/3 10 10
Made the procedure more acceptable - - - 5/3 10 10
B
Question Parents (n) Score (median) Range Doctors* (n) Score (median) Range
The use of intranasal sedation (placebo) by MAD:
Helped 19 5 3-7 5/3 3 2-4
Level of child’s outlook 19 5.8 5-7 5/3 3 2-4
Level of parents’ outlook 19 4.9 3-7 5/3 5 3-7
Level of doctors’ outlook - - 5/3 4 3-5
Level of child’s tolerance of procedures 19 8.5 7-10 5/3 8 7-9
Would recommend to other parents 19 4 3-6 - -
Would recommend to other doctors - - 5/3 3 1-5
Would like to see MAD used routinely 19 4 3-6 5/3 3 1-5
Made the procedure more acceptable - - - 5/3 3 1-5
*unbiased medical doctors involved in the painful or diagnostic procedures (text for details).
INKM, intranasal midazolam and ketamine.
MAD, mucosal atomiser device.
Buonsenso et al. BMC Pediatrics 2014, 14:67 Page 5 of 8
http://www.biomedcentral.com/1471-2431/14/67
Statistical analysis
The mean degree of sedation achieved in the sedation-
group was statistically higher than that of the placebo-group
(p <0.0001). In the sedation-group, we did not find statisti-
cally significant correlation between MOPS, start time, end
time and duration of sedation with age, weight and number
of procedures. The correlation between ethnicity and degree
of sedation achieved has not been performed due to the low
number of patients evaluated.
Cost analysis
The preparation of Midazolam (Ipnovel 5 mg/mL,
Roche, Milano, Italy) we used (1 mL vial, concentration:
5 mg/mL) has a price of 4.70 euro (6.41 $), which means
that 0.5 mg has a theoretical price of 0.47 euro (0.641 $);
therefore for every child’s kilogram a purchase of 0.47
euro (0.641 $) would be required. The preparation of
Ketamine (Ketamina Molteni 50 mg/mL, Firenze, Italy)
we used (2 mL vial, concentration: 50 mg/mL) has a
price of 4.916 (6.706 $) euro per vial, which means that
2 mg has a theoretical price of 0.196 euro (0.267 $),
therefore for every child’s kilogram a purchase of 0.196
euro (0.267 $) would be required. The MAD we used
has a prize for the single device of 3.96 euro (5.36 $).
The same device can be used for all the three procedures
every single child underwent; after its use, the device
need to be thrown away. For example, to sedate a 10 kg
child with our protocol, a total purchase of 10.59 euro
(14.44 $) (6.66 euro (9.086 $) for drugs plus 3.96 euro
(5.36 $) for MAD) would be needed.
Discussion
This study shows that INKM administered via MAD
seems to be effective and safe when gastric washings in
anxious and uncooperative children need to be performed
to diagnose TB. All patients achieved an adequate level of
sedation throughout each procedure, with a statistically
significant difference compared to the placebo-group in
the degree of MOPS reduction. Both the medical staff and
the patient’s parents reported a significant degree of
satisfaction with the INKM protocol used to perform
gastric aspirates respect to the placebo group. There
were no serious side effects, such as oxygen desaturation,
bradycardia, hypotension or apnoea. The only side effect
registered was post-sedation agitation. As described in
literature, the use of Ketamine is known to result in an
agitated, confused, and combative child. There has been
no documented effective strategy in the literature to
manage this problem but these adverse reactions are
usually transient and completely recover spontan-
eously without any adverse consequences [21]. On the
other hand, several studies revealed that intranasal
Midazolam administered by MAD or by drops resulted in
nasal burning and a bitter taste in up to 66% of patients,
making the experience unpleasant and the procedure
more difficult to complete [22,23]. The administration
of intranasal Lidocaine prior to the use of intranasal
Midazolam has been reported to be beneficial in
reducing the burning sensation from the intranasal
Midazolam [11]. In our experience we decided to not use
intranasal Lidocaine before the Midazolam administration
due to the local anesthetic properties of the Ketamine able
to avoid any nasal discomfort related to intranasal
Midazolam. Recent studies also reported the use of much
higher doses of intranasal Ketamine (up to 9 mg/kg) to
perform different painful procedures in pediatric age
[24,25]. In our experience we decided to utilize a relatively
low dose of Ketamine to evaluate both its efficacy and also
to provide a safety dose of the drug able to avoid the more
frequent side effects related to its use, such as nausea,
vomiting, respiratory depression, and laryngospasm.
Recently, it has been reported that high doses of Ketamine
in different procedures involving major airways, such as
gastroscopy and bronchoscopy, are responsible of the
appearance of the laryngospasm in about 10% of cases
needed O2 ventilation by face-mask and continuous
positive airway pressure to be resolved [11,26,27]. Our
results showed that, despite the low doses of intranasal
Ketamine, we were able to complete all the procedures
without major side effects, such as laryngospam, in treated
children making this procedure very easy. In fact, the only
side effect observed in the sedation group was the
post-sedation agitation in 14.3% of cases. Obviously, a
slightly higher dose of Ketamine could have induced
a higher sedation allowing to complete the procedure
by a single physician in every cases, particularly in
younger children, since other authors found that
younger children required higher dosage in milligrams
per kilogram of Ketamine for adequate sedation [28].
This may be explained by the faster metabolism and
renal clearance leading to a shorter half-life of Ketamine
in children compared to adults [29,30]. Nevertheless,
Hosseini Jahromi SA et al. recently found that by
increasing the dose of intranasal Ketamine (0.5 mg/kg
vs 3 mg/kg), the children developed less sedation than
those who received a lower dose of Ketamine [25],
suggesting that a dosage as low as 0.5 mg/kg intranasal
Ketamine might be suitable for achieving an adequate
therapeutic action (sedation and anxiolysis) combined
with lesser side effects because there is a dose–response
correlation between Ketamine and its side effects
[8,14,28]. Similarly, Yeaman F et al. recently demonstrated
that sub-dissociative doses of intranasal Ketamine
provided adequate analgesia by 30 min for most
paediatric patients aged 3-13 years admitted to the
emergency department with moderate to severe pain from
isolated limb injury [31]. The PICHFORK (Pain In
CHildren Fentanyl OR Ketamine) trial [32] aimed to
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compare the efficacy of intranasal Ketamine and Fentanyl
in the relief of moderate to severe pain in children with
limb injuries will use low doses of intranasal Ketamine
(1 mg/kg). All these findings support our choice of using
moderate doses of Ketamine (2 mg/kg) in order to achieve
a proper sedative/analgesic effect while reducing the
possibility of severe adverse events, making our protocol
applicable also in pediatric wards. Moreover, in our study,
we did not applied local anesthetics on nasogastric tube,
for two reasons. Firstly, in current literature it is not
recommended for the specific use of collect samples for
the detection of Mycobacterium tuberculosis (MTB) in
children [18]; secondly, local anesthetics have a well
established antimicrobial activity versus bacteria and fungi
[33-35]. Although this aspect has not yet been studied
versus mycobacteria, the even low risk of potentially
reducing the possibility of culture MTB induced us to not
apply local anesthetics on nasogastric tubes. Moreover,
even though local anesthetics may reduce the pain related
to NGTI, it would not change the experience of the child
undergoing the procedure. This is particularly important
for those cases, such as suspected TB patients, who
need to be submitted to frequent NGTIs to perform
the diagnosis and for treatment monitoring. The advantage
of a procedural sedation over the local anesthetic, in such
situations, is also to improve the all experience for both
doctors, physicians and parents particularly when a single
child need to undergo this procedure more times. Our
results confirm all those findings making our INKM-based
protocol a simple, safe and affordable way to perform this
procedure in uncooperative children. The use of this
protocol would allow even a single nurse or physician
(after a brief training program) to perform the procedure,
ensuring pain relief and patients and parents’ comfort. Our
results could be particularly useful in low-income high
TB-burden countries, where a big number of gastric
washings would need to be performed daily and
where there are limited physician and only a few with
specific training in procedural sedation [36]. Moreover,
our protocol had low drug-related costs and allowed to
reduce the number of health care workers necessary to
perform the procedure. Nevertheless, these savings should
be counterbalanced with costs related to monitoring
(both health care workers and equipment). In fact, we
found a long median recovery time (79.7 min). The
recovery time has wide individual variations and depends
on the doses of medications and clearance in the body.
However, the relatively long recovery time is not a major
problem in ward settings and day hospital regimens.
Limitations of the study
The first one is the low number of children evaluated.
This makes the data difficult to interpret and did not
allow us to find any variables (gender, weight, ethnicity,
etc) that could be associated with a higher degree of
sedation. Moreover, the low number of children did not
allow us to strongly affirm the safety of our protocol,
although the preliminary results of our study are
promising. If our results would be confirmed by a
multicentre, prospective, controlled, randomized trial
our protocol could be easily introduced in general
practice not only for gastric washings in children with
suspected TB but also for different kind of procedural
sedation in uncooperative children.
Secondly, the subjectivity of pain measurement by
both parents and physicians is a clear limitation which is
difficult to overcome. Several sedation scoring scales
have been described for children but in current literature
there are no comparison studies of all scales; nevertheless,
the validity of MOPS has been clearly described [19,20].
In this regard, other pain scores have been described in
literature. Among those, the FLACC scale have been
widely used for post-operative and non post-operative
pain assessment, and could have been used also in our
study [37]. Nevertheless, we decided to not use FLACC
score because the Authors clearly showed that this score
can be high during non-painful procedures and during
restraint phase of painful procedures, indicating that
FLACC scale measures a composite of pain and distress in
young children, in this way altering the application of this
score in our study [38]. Finally, we analyzed drug-related
costs, which are affordable even in low income countries
and allow to perform procedures by a lower number of
health care workers, but clearly need to be counterbalanced
by monitoring and equipment costs, making difficult to
establish the cheapest way to perform these procedures.
On the other hand, parents appreciation appeared clear.
Therefore, the use of the protocol should be evaluated
depending on local resources.
Conclusions
INKM administered by MAD could be a simple and
non-invasive approach for the sedation of children
undergoing gastric washings and other minor painful
procedures or diagnostic investigations. Despite several
study limitations, INKM has demonstrated a good level
of efficacy and safety in our series. Further studies are
needed to clarify the potential of this protocol for the
sedation of children in general pediatric departments
and emergency rooms, in both high and low-income
countries, mainly to better understand the ideal dose
of intranasal Ketamine needed to perform effectively
different pediatric procedures without serious side effects
for the children.
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